Survival Outcomes and Predictors of Mortality, Re-bleeding and Complications for Acute Severe Variceal Bleeding Requiring Balloon Tamponade

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Sep 26

PMID 36157875

Authors

Charlotte Y Keung

Aparna Morgan

Suong T Le

Marcus Robertson

Paul Urquhart

Michael P Swan

Affiliations

Soon will be listed here.

Abstract

Background: Acute severe variceal bleeding (AVB) refractory to medical and endoscopic therapy is infrequent but associated with high mortality. Historical cohort studies from 1970-1980s no longer represent the current population as balloon tamponade is no longer first-line therapy for variceal bleeding; treatments including vasoactive therapies, intravenous antibiotics, endoscopic variceal band ligation are routinely used, and there is improved access to definitive treatments including transjugular intrahepatic portosystemic shunts. However, only a few studies from the current era exist to describe the practice of balloon tamponade, its outcomes, and predictors with a requirement for further updated information.

Aim: To describe current management of AVB requiring balloon tamponade and identify the outcomes and predictors of mortality, re-bleeding and complications.

Methods: A retrospective multi-centre cohort study of 80 adult patients across two large tertiary health networks from 2008 to 2019 in Australia who underwent balloon tamponade using a Sengstaken-Blakemore tube (SBT) were included for analysis. Patients were identified using coding for balloon tamponade. The primary outcome of this study was all-cause mortality at 6 wk after the index AVB. Secondary outcomes included re-bleeding during hospitalisation and complications of balloon tamponade. Predictors of these outcomes were determined using univariate and multivariate binomial regression.

Results: The all-cause mortality rates during admission and at 6-, 26- and 52 wk were 48.8%, 51.2% and 53.8%, respectively. Primary haemostasis was achieved in 91.3% and re-bleeding during hospitalisation occurred in 34.2%. Independent predictors of 6 wk mortality on multivariate analysis included the Model for Endstage Liver disease (MELD) score (OR 1.21, 95%CI 1.06-1.41, 0.006), advanced hepatocellular carcinoma (OR 11.51, 95%CI 1.61-82.20, 0.015) and re-bleeding (OR 13.06, 95%CI 3.06-55.71, < 0.001). There were no relevant predictors of re-bleeding but a large proportion in which this occurred did not survive 6 wk (76.0% 24%). Although mucosal trauma was the most common documented complication after SBT insertion (89.5%), serious complications from SBT insertion were uncommon (6.3%) and included 1 patient who died from oesophageal perforation.

Conclusion: In refractory AVB, balloon tamponade salvage therapy is associated with high rates of primary haemostasis with low rates of serious complications. Re-bleeding and mortality however, remain high.

References

Rockall T, Logan R, Devlin H, Northfield T . Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996; 38(3):316-21. PMC: 1383057. DOI: 10.1136/gut.38.3.316. View

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Avgerinos A, Armonis A . Balloon tamponade technique and efficacy in variceal haemorrhage. Scand J Gastroenterol Suppl. 1994; 207:11-6. DOI: 10.3109/00365529409104188. View

Nadler J, Stankovic N, Uber A, Holmberg M, Sanchez L, Wolfe R . Outcomes in variceal hemorrhage following the use of a balloon tamponade device. Am J Emerg Med. 2017; 35(10):1500-1502. PMC: 5623073. DOI: 10.1016/j.ajem.2017.04.035. View

Rodrigues S, Cardenas A, Escorsell A, Bosch J . Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis. Semin Liver Dis. 2019; 39(2):178-194. DOI: 10.1055/s-0039-1678726. View

Teres J, Planas R, Panes J, Salmeron J, Mas A, Bosch J . Vasopressin/nitroglycerin infusion vs. esophageal tamponade in the treatment of acute variceal bleeding: a randomized controlled trial. Hepatology. 1990; 11(6):964-8. DOI: 10.1002/hep.1840110609. View

Amitrano L, Guardascione M, Manguso F, Bennato R, Bove A, DeNucci C . The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors. Am J Gastroenterol. 2012; 107(12):1872-8. DOI: 10.1038/ajg.2012.313. View

Bambha K, Kim W, Pedersen R, Bida J, Kremers W, Kamath P . Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008; 57(6):814-20. DOI: 10.1136/gut.2007.137489. View

Vreeburg E, Terwee C, Snel P, Rauws E, Bartelsman J, Meulen J . Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut. 1999; 44(3):331-5. PMC: 1727413. DOI: 10.1136/gut.44.3.331. View

10.

Robertson M, Majumdar A, Boyapati R, Chung W, Worland T, Terbah R . Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. Gastrointest Endosc. 2015; 83(6):1151-60. DOI: 10.1016/j.gie.2015.10.021. View

11.

Haddock G, Garden O, McKee R, ANDERSON J, Carter D . Esophageal tamponade in the management of acute variceal hemorrhage. Dig Dis Sci. 1989; 34(6):913-8. DOI: 10.1007/BF01540278. View

12.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

13.

Saltzman J, Tabak Y, Hyett B, Sun X, Travis A, Johannes R . A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc. 2011; 74(6):1215-24. DOI: 10.1016/j.gie.2011.06.024. View

14.

Bridwell R, Long B, Ramzy M, Gottlieb M . Balloon Tamponade for the Management of Gastrointestinal Bleeding. J Emerg Med. 2022; 62(4):545-558. DOI: 10.1016/j.jemermed.2021.11.004. View

15.

Bajaj J, Ananthakrishnan A, Saeian K . Survey of attitudes of AASLD members toward balloon tamponade. Hepatology. 2005; 41(6):1435-6. DOI: 10.1002/hep.20737. View

16.

Blatchford O, Murray W, Blatchford M . A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000; 356(9238):1318-21. DOI: 10.1016/S0140-6736(00)02816-6. View

17.

Garcia-Pagan J, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A . Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010; 362(25):2370-9. DOI: 10.1056/NEJMoa0910102. View

18.

Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R . A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2013; 146(2):412-19.e3. DOI: 10.1053/j.gastro.2013.10.018. View

19.

Tripathi D, Stanley A, Hayes P, Patch D, Millson C, Mehrzad H . U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015; 64(11):1680-704. PMC: 4680175. DOI: 10.1136/gutjnl-2015-309262. View

20.

Choi J, Jo Y, Lee S, Kim W, Oh H, Kim C . Outcomes of patients treated with Sengstaken-Blakemore tube for uncontrolled variceal hemorrhage. Korean J Intern Med. 2017; 33(4):696-704. PMC: 6030415. DOI: 10.3904/kjim.2016.339. View